Baxter, Onconova Therapeutics deal

Onconova granted Baxter exclusive rights to commercialize rigosertib in Europe. Onconova will receive $50 million up front and

Read the full 186 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE